Press Release: 25 Years of trenzyme – A Quarter Century as a Reliable Research Partner for Biotech and Pharma Worldwide
Konstanz-based biotechnology company trenzyme celebrates its 25th anniversary
Konstanz, June 2025 – trenzyme GmbH celebrates its 25th anniversary as a leading research service provider for cell line development, iPSC differentiation, and recombinant protein production. Since its founding in 2000, trenzyme has continuously evolved and today supports customers worldwide in the fields of biotechnology, the pharmaceutical industry, diagnostics, and academic research with high-quality, customized solutions.
“I am incredibly proud of what we have achieved over the past 25 years,” says Dr. Reinhold Horlacher, founder and Managing Director of trenzyme GmbH. “Our highly qualified team of scientists and dedicated experts has contributed with great passion and innovative spirit to making us a valued partner for leading companies and research institutions around the world today. Despite the challenges the entire industry has faced in recent years, we look to the future with confidence.”
Many Years of Expertise and Customized Solutions for Research
trenzyme offers a broad range of research services – from the development of stable cell lines and GMP-compliant cell line production to recombinant protein production. The produced cell lines are used, for example, in drug development and active substance testing, while the recombinant proteins play a crucial role in cancer research and diagnostics, among other fields.
A particular success factor is the close collaboration with customers. Through transparent processes and efficient project management, trenzyme ensures that each project is handled individually and implemented optimally. “Our customers – whether start-ups or large pharmaceutical companies – especially appreciate our direct and personal communication. We understand their specific requirements and develop solutions that truly fit their projects,” explains Dr. Horlacher.
Continuing on the Path to Success Despite Challenges
Like the entire industry, trenzyme has faced major challenges in recent years – from the aftermath of the pandemic to economic uncertainties caused by war on European soil and challenging global trade relations. Yet the company has successfully held its ground and continued its growth trajectory. “The past years have shown how important agility and innovation are in our industry,” says Horlacher. “We have continuously developed our technologies and deliberately expanded our service portfolio to continue offering our customers the best possible support in the future. During the coronavirus pandemic, we were one of the first providers in Europe to offer essential components for the development of vaccines and tests – this gave us a significant boost.”
Looking to the Future
With 25 years of experience, a highly qualified team, and a clear vision for the future, trenzyme remains a reliable partner for research and development. “Our goal is to continue delivering innovative solutions and to enable the next scientific breakthroughs together with our customers,” emphasizes Dr. Horlacher. “I thank all our customers and employees who have made this success possible, and I look forward to the coming years full of exciting projects and new challenges.”
About trenzyme GmbH
trenzyme GmbH is a leading contract research service provider based in Konstanz. Since 2000, the company has been supporting international customers from the pharmaceutical, biotech, and academic research sectors with high-quality, customized solutions in the fields of cell line development, iPSC differentiation, and recombinant protein production. With an experienced team and a strong focus on quality and customer satisfaction, trenzyme drives biotechnological and pharmaceutical research forward.
trenzyme GmbH
Byk-Gulden-Straße 2
78467 Konstanz, Deutschland
Telefon: +49 (0) 75 31 / 1 22 90 – 0
E-Mail: contact@trenzyme.com
www.trenzyme.com
https://trenzyme.com/wp-content/uploads/Press-Release_25-years-anniversary-trenzyme-GmbH_website.pdf
